{"filings":[{"id":92615,"accession_number":"0001628280-26-028854","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q1 revenue $177M (+5% YoY); GAAP EPS $0.07, non-GAAP $0.60; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $177.4M (+5% YoY); EXPAREL $143.3M (+5%), ZILRETTA $26.8M (+15%), iovera° $6.2M (+21%).","GAAP net income $2.9M ($0.07/diluted); non-GAAP net income $24.5M ($0.60/diluted); adjusted EBITDA $40.2M.","Repurchased 2.2M shares for $50M at avg $22.28; $100M remains under authorization through Dec 2026.","Completed ZILRETTA Phase 3 enrollment for shoulder OA; topline readout expected by end of 2026.","Reiterated FY 2026 guidance: EXPAREL $600-620M, total revenue $745-770M, non-GAAP gross margin 77-79%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":177376000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103570,"accession_number":"0001628280-26-012238","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira BioSciences reports Q4 2025 revenue of $196.9M, up 5%, and full-year 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $196.9M (5% increase vs Q4 2024); EXPAREL sales $155.8M (+5%)","Full-year 2025 revenue $726.4M; GAAP net income $7.0M vs net loss of $99.6M in 2024","Repurchased 5.9M shares for $150.0M in 2025; $150M remaining authorization through Dec 2026","2026 guidance: EXPAREL net sales $600-620M, total revenue $745-770M, gross margin 77-79%","Strategic partnership with LG Chem for EXPAREL in select Asian-Pacific markets; Samit Hirawat appointed to board"],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":726411000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103569,"accession_number":"0001628280-26-003717","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences appoints Dr. Samit Hirawat (ex-BMS CMO) to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 members; Hirawat appointed as Class III director, effective immediately.","Hirawat brings >25 years industry experience; most recently CMO, EVP, Head of Global Drug Development at Bristol Myers Squibb.","Hirawat appointed to Science and Technology Committee; receives standard non-employee director compensation.","Board determined Hirawat is independent under Nasdaq listing standards; no related party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103568,"accession_number":"0001628280-26-001335","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira reports preliminary 2025 revenue of $726.4M; EXPAREL sales record high with 7% volume growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $726.4M vs $701.0M in FY2024, up 3.6%.","Q4 EXPAREL net sales $155.8M (record) vs $147.7M in Q4 2024, 7% volume growth.","Full-year EXPAREL net sales $575.1M vs $549.0M (+4.8%); ZILRETTA flat at $116.6M.","Repurchased 2.0M shares for $50.0M in Q4; $150M remains under current authorization.","Preliminary unaudited; full Q4/fiscal 2025 results and guidance expected later in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":726411000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119833,"accession_number":"0001628280-25-050145","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q3 total rev $179.5M (+6% YoY); GAAP net income $5.4M vs loss; guides FY rev lower, gross margin higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $179.5M, up 6% YoY; EXPAREL $139.9M (volume +9% offset by mix and discounting).","GAAP net income $5.4M ($0.12/share) vs net loss of $143.5M in Q3 2024, which included $163.2M goodwill impairment.","Adjusted EBITDA $49.4M vs $54.7M; non-GAAP net income $31.8M ($0.72 diluted) vs $38.2M ($0.79) prior year.","FY2025 revenue guidance lowered to $725-735M from $730-750M; non-GAAP gross margin raised to 80-82% from 78-80%.","Repurchased 2.0M shares for $50M; $200M remaining on authorization; exclusive license of AMT-143 (ropivacaine) with $5M upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":529538000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136386,"accession_number":"0001396814-25-000100","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q2 2025 revenue $181.1M, GAAP net loss $4.8M; guidance updated, legal win $28.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $181.1M (+2% YoY); EXPAREL $142.9M, ZILRETTA $31.3M, iovera° $5.6M.","GAAP net loss $4.8M ($0.11/share) vs net income $18.9M in Q2 2024; non-GAAP net income $36.0M.","Received $28.3M from favorable court ruling on EXPAREL royalty repayment from RDF in July 2025.","New $300M five-year revolving credit facility replaces prior term loan; reduces interest expense 60bps in 2026.","2025 guidance: revenue narrowed to $730M-$750M; non-GAAP gross margin raised to 78-80%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":350022000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136385,"accession_number":"0001396814-25-000093","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences cuts 71 jobs (8% of workforce); decommissions 45-liter EXPAREL suite in San Diego","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 71 employees (~8% of total) from Technical Operations at San Diego Science Center Campus.","Pre-tax charges of $2.4M-$2.8M in Q3 2025 for employee termination benefits, plus $5.4M accelerated depreciation.","Decommissioning 45-liter manufacturing suite after bringing two larger 200+ liter suites online in San Diego and Swindon, UK.","Expects annual operating expense savings of ~$13 million from the reduction in force.","New large-scale suites produce bulk EXPAREL volumes approximately four-fold greater per batch, improving gross margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136384,"accession_number":"0001104659-25-065979","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Pacira enters $300M revolving credit facility, replaces prior term loan A","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$300M senior secured revolver matures July 3, 2030; includes $10M LC sublimit and $15M swingline.","Proceeds used to repay and terminate existing term loan A facility; no prepayment penalties.","Interest rates: SOFR + 2.50%-3.25% or base rate + 1.50%-2.25%, based on leverage ratio.","Facility secured by substantially all assets of Pacira and subsidiary guarantors.","Incremental facility capacity up to greater of $225M or 100% Consolidated EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153536,"accession_number":"0001396814-25-000089","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Pacira shareholders approve 2.5M share increase to equity plan; say-on-pay fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended 2011 Plan adding 2,500,000 new shares for future grants.","Advisory say-on-pay resolution failed: 14,752,829 for, 22,595,202 against, 33,777 abstain.","Board will hold annual say-on-pay votes based on frequency vote (1 year: 35,312,982 votes).","Three Class II directors elected: Bigal, Lee, Young; no other director changes.","KPMG ratified as auditor for FY 2025 with 40,022,569 for, 352,947 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153535,"accession_number":"0001396814-25-000060","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q1 revenue $168.9M, net income $4.8M; EXPAREL exclusivity extended to 2039","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $168.9M (+1% YoY); GAAP net income $4.8M ($0.10) vs $9.0M ($0.19) a year ago.","EXPAREL net sales $136.5M (+3% YoY) with 7% daily volume growth; ZILRETTA $23.3M (-10%).","Patent litigation settled with Fresenius Kabi; limited-volume entry starts at high single-digit % of U.S. volume, exclusivity to 2039.","Court ruling eliminates EXPAREL royalty obligation to RDF; future payments stopped, repayment sought.","Reiterates FY2025 guidance: revenue $725-765M, non-GAAP gross margin 76-78%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":168923000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153534,"accession_number":"0001396814-25-000055","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pacira Biosciences authorizes $300M share repurchase program through Dec 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved $300M stock buyback, effective immediately, replacing the May 7, 2024 program.","Repurchases may be made on open market or via privately negotiated transactions at management's discretion.","Program expires December 31, 2026; can be suspended or discontinued at any time by the company.","No obligation to repurchase any specific number of shares under the authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153533,"accession_number":"0001396814-25-000051","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Pacira settles EXPAREL patent litigation; Fresenius licensed to sell generic from early 2030","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Fresenius Kabi, eVenus, Jiangsu Hengrui resolves all patent suits over EXPAREL (bupivacaine liposome).","Fresenius gets license to sell volume-limited generic starting on confidential date in early 2030, before last patent expiry in 2044.","Volume-limited percentages start at high-single-digit, increase to low-thirties in 2033, capped at high-thirties for final three years.","Unlimited generic license granted no earlier than 2039.","Pacira pays Fresenius $7 million for expected litigation cost savings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172262,"accession_number":"0001396814-25-000048","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Pacira BioSciences adopts majority voting standard for uncontested director elections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Third Amended and Restated Bylaws effective March 12, 2025.","Majority voting applies to uncontested director elections; plurality retained for contested.","No other changes were made to the prior bylaws.","Change is effective immediately upon approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172261,"accession_number":"0001396814-25-000039","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira BioSciences: 2024 record rev $701M, GAAP net loss $99.6M on $163M impairment; FY2025 rev guide $725M-$765M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 rev $187.3M (+3% YoY); full-year rev $701.0M (+4%); EXPAREL $549M, ZILRETTA $118M, iovera $22.8M.","Full-year GAAP net loss $99.6M ($2.15 loss/share) includes $163.2M goodwill impairment; adjusted EBITDA $223.9M (+4%).","Non-GAAP net income $157.7M ($3.20 diluted); Q4 non-GAAP net income $44.3M ($0.91 diluted).","Acquired remaining 81% of GQ Bio for ~$32M net; adds genetic medicine platform, eliminates future milestones.","FY2025 guidance: rev $725-765M, non-GAAP gross margin 76-78%, R&D $90-105M, SG&A $290-320M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":700966000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172260,"accession_number":"0001396814-25-000022","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences appoints Laura Brege as Board Chair; two directors retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul J. Hastings (former Chair) and Andreas Wicki retired effective Jan. 28, 2025; no disagreement cited.","Laura Brege appointed Chair; brings 30 years pharma/biotech executive experience.","Board reduced from 12 to 9 directors; 8 of 9 are independent; 5 joined since Oct. 2023.","Alethia Young succeeds Brege as Audit Committee Chair; other committee assignments refreshed.","Brege previously held leadership roles at BridgeBio, Onyx Pharmaceuticals, and COR Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172259,"accession_number":"0001396814-25-000017","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira appoints Brendan Teehan as CCO, Krys Corbett as CBO; adds 785K shares to inducement plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan Teehan named Chief Commercial Officer effective Jan 21, 2025; previously COO at Acadia Pharmaceuticals.","Krys Corbett appointed Chief Business Officer; most recently led portfolio strategy at Lyell Immunopharma.","Daryl Gaugler transitions from COO to EVP Commercial Operations; compensation and agreement unchanged.","Board adopted amended inducement plan adding 785,000 shares (total 2,310,000) and extending term to Jan 2035.","Company cites '5x30' strategy to grow commercial base and advance pipeline toward innovative biopharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172258,"accession_number":"0001396814-25-000011","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira preliminary FY2024 revenue $701M (+3.9% YoY); announces 5x30 growth plan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenue of $701.0M, up from $675.0M in 2023; Q4 EXPAREL $147.7M.","EXPAREL net sales $549.0M, ZILRETTA $118.1M, iovera° $22.8M for full year.","Unveils 5x30 plan: treat >3M patients/year, double-digit revenue CAGR, 5pp gross margin improvement by 2030.","Inducement grants: options for 20,300 shares and RSUs for 30,400 shares at $18.40.","Revenue preliminary and unaudited; full Q4 and FY results with guidance expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":700966000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189254,"accession_number":"0001396814-24-000140","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Pacira Q3 revenue $168.6M, net loss $143.5M on $163.2M goodwill impairment; affirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $168.6M; EXPAREL $132.0M (+2.6%), ZILRETTA $28.4M, iovera° $5.7M.","GAAP net loss $143.5M ($3.11/sh) on $163.2M goodwill impairment; non-GAAP net income $38.2M.","Adjusted EBITDA $54.7M; cash $453.8M. FY 2024 guidance reaffirmed ($680M-$705M rev).","CMS final rule confirms separate NOPAIN reimbursement for EXPAREL/iovera° starting Jan 1, 2025; new J-code J0666 effective same date.","Executive employment agreements amended for Gaugler, Slonin, Williams: enhanced severance (12-mo salary continuation; 18-mo on change of control)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":513713000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189253,"accession_number":"0001396814-24-000129","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences appoints Shawn Cross as CFO effective Oct 21, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn Cross appointed CFO effective Oct 21, 2024; succeeds interim CFO Lauren Riker, who remains SVP of Finance.","Cross brings >25 years of biopharma experience; former CEO/President/CFO of Applied Molecular Transport.","Annual base salary $525K; annual bonus target 50% of base; inducement awards of 200K stock options and 75K RSUs.","Inducement awards vest over four years; option exercise price equals Nov 4, 2024 closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205751,"accession_number":"0001396814-24-000124","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pacira names Lauren Riker interim CFO; Reinhart departs Sept 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Charles Reinhart departs Sept 30, 2024; will serve as consultant for 9 months.","Lauren Riker, SVP of Finance, appointed interim CFO effective Oct 1, 2024.","Riker's base salary unchanged at $374,700; bonus target 50%; receives one-time $75k bonus.","Riker to serve as interim CFO until permanent successor identified.","No changes to existing employment agreement or other compensation terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205750,"accession_number":"0001396814-24-000120","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pacira board rejects director Laura Brege's resignation after majority withhold vote","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laura Brege received majority withhold votes at 2024 annual meeting; tendered resignation per company policy.","Independent directors unanimously rejected resignation after considering her qualifications, attendance, and prior support.","Brege stepped down from HLS Therapeutics board on Aug 7 to address overboarding; remains Pacira director until 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205749,"accession_number":"0001396814-24-000103","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pacira's EXPAREL patent invalidated by New Jersey court; company plans appeal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for D.N.J. ruled Pacira's U.S. Patent No. 11,033,495 for EXPAREL is invalid.","Company intends to appeal the decision to the U.S. Court of Appeals for the Federal Circuit.","Three separate infringement suits against eVenus remain ongoing; additional patents pending.","CEO Frank D. Lee stated belief in patent strength and that EXPAREL franchise is well protected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205748,"accession_number":"0001396814-24-000097","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q2 2024: Revenue $178M, GAAP EPS $0.39; CMS proposes EXPAREL outpatient reimbursement under NOPAIN","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues of $178.0M, up 5% YoY; EXPAREL sales $136.9M (+1.3%), ZILRETTA $30.7M.","GAAP net income $18.9M ($0.39 diluted EPS) vs $25.8M ($0.51) in Q2 2023.","Non-GAAP net income $44.2M ($0.89 diluted EPS) vs $36.0M ($0.71) a year ago; adjusted EBITDA $62.1M.","CMS proposed rule would separately reimburse EXPAREL in HOPD/ASC starting Jan 2025 under NOPAIN Act.","Full-year 2024 revenue guidance reiterated at $680M-$705M; $150M share repurchase program ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":345140000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222703,"accession_number":"0001396814-24-000057","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Pacira BioSciences director Gary Pace to retire June 30; consulting deal; shareholder votes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Gary Pace to retire from Board June 30, 2024; no disagreement with company.","Consulting agreement amendment: one-year term from July 2024 to June 2025, $3,200/quarter for up to 8 hours.","Shareholders elected Class I directors: Laura Brege, Mark Froimson, Mark Kronenfeld, Michael Yang.","KPMG ratified as independent auditor for FY 2024 with ~43.9M for, 0.2M against.","Advisory say-on-pay vote passed with ~37.2M for, 4.1M against, 2.7M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222702,"accession_number":"0001104659-24-061135","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Pacira BioSciences issues $287.5M convertible notes, repurchases $200M of 2025 notes and $25M stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $250.0M (plus $37.5M option) of 2.125% Convertible Senior Notes due 2029; net proceeds ~$278.4M.","Used ~$191.4M to repurchase $200M aggregate principal of outstanding 0.750% convertible notes due 2025.","Used ~$25.0M to repurchase 837,240 shares of common stock.","Entered into capped call transactions to reduce potential dilution upon conversion, with cap price ~$53.75/share.","Initial conversion price ~$39.56/share, representing ~32.5% premium over closing price of $29.86 on May 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222701,"accession_number":"0001104659-24-058675","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Pacira proposes $250M convertible note offering due 2029; up to $50M share repurchase","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Proposed offering of $250M aggregate principal of Convertible Senior Notes due 2029, with initial purchasers' option for additional $37.5M.","Proceeds to repurchase portion of outstanding 0.750% 2025 Notes, fund capped call transactions, and repurchase up to $50M of common stock.","Capped call transactions expected to reduce dilution upon conversion and offset cash payments in excess of principal amount.","Entered First Amendment to Credit Agreement to permit $150M share repurchase program and the proposed note offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222700,"accession_number":"0001396814-24-000044","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Pacira Q1 net income $9.0M ($0.19 EPS); announces $150M share repurchase","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $9.0M ($0.19/sh) vs net loss $19.5M ($0.43 loss) YoY.","Total revenue $167.1M, up from $160.3M YoY; EXPAREL net sales $132.4M.","Adjusted EBITDA $44.6M vs $41.9M YoY; cash flow from ops $49.1M.","Board authorizes $150M share repurchase program through Dec 2026.","FY2024 guidance reaffirmed: revenue $680M-$705M, non-GAAP gross margin 74%-76%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":167117000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}